{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:03Z","timestamp":1776408663752,"version":"3.51.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000995","name":"Australian National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Venetoclax and hypomethylating agent combination therapy is now the standard of care in acute myeloid leukemia (AML) for patients ineligible for intensive therapy, including the elderly; however, venetoclax and low-dose cytarabine remain a viable option for select patients. Relapse in this cohort remains a significant challenge, with a poor prognosis and an unmet need for further treatment options. This case discusses an elderly patient with\n                    <jats:italic>NPM1-<\/jats:italic>\n                    mutated AML successfully retreated with time-limited venetoclax and low-dose cytarabine at relapse. The sustained response observed contributes to the limited literature on the efficacy of re-treatment with venetoclax-based therapy in this setting. However, prospective data are required to assess the efficacy and safety of this strategy as well as to establish the role of molecular monitoring. The role of time-limited venetoclax therapy for preventing treatment resistance and limiting treatment-related adverse effects remains an important question in the cohort ineligible for intensive therapies, given the poor prognosis and limited options of relapsed\/refractory AML post-venetoclax and hypomethylating agent therapy.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06781-z","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:15:54Z","timestamp":1771287354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: a case report and literature review"],"prefix":"10.1007","volume":"105","author":[{"given":"Jun Yen","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Gullapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jad","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipti","family":"Talaulikar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"6781_CR1","volume-title":"World health organization classification of tumours of Haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) World health organization classification of tumours of Haematopoietic and lymphoid tissues. IARC, Lyon"},{"key":"6781_CR2","unstructured":"WHO Classification of Tumours Editorial Board Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024. (WHO classification of tumours series, 5th ed.; vol. 11). https:\/\/publications.iarc.who.int\/637"},{"key":"6781_CR3","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL et al Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024\/11\/21;144(21).","DOI":"10.1182\/blood.2024025409"},{"key":"6781_CR4","unstructured":"Wittwer JW Excel Timeline Templates by Vertex42.com"},{"key":"6781_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-016-3195-z","volume":"17","author":"CA Miller","year":"2016","unstructured":"Miller CA, McMichael J, Dang HX, Maher CA, Ding L, Ley TJ et al (2016) Visualizing tumor evolution with the fishplot package for R. BMC Genomics 17:1 2016-11-07;17(1)","journal-title":"BMC Genomics"},{"issue":"7","key":"6781_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):8\u201313","journal-title":"N Engl J Med"},{"key":"6781_CR7","doi-asserted-by":"crossref","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K et al Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020\/06\/11;135(24).","DOI":"10.1182\/blood.2020004856"},{"key":"6781_CR8","doi-asserted-by":"crossref","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H et al Long-term follow\u2010up of VIALE\u2010A: venetoclax and Azacitidine in chemotherapy\u2010ineligible untreated acute myeloid leukemia. Am J Hematol. 2024\/04\/01;99(4).","DOI":"10.1002\/ajh.27246"},{"issue":"25","key":"6781_CR9","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/blood.2022016963","volume":"140","author":"AH Wei","year":"2022","unstructured":"Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I et al (2022) Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood 140(25):2754\u20132756","journal-title":"Blood"},{"key":"6781_CR10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.252569","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F et al (2021) Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2020.252569","journal-title":"Haematologica"},{"key":"6781_CR11","doi-asserted-by":"crossref","unstructured":"Zucenka A, Pileckyte R, Trociukas I, Peceliunas V, Vaitekenaite V, Maneikis K et al Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies. Eur J Haematol. 2021\/01\/01;106(1).","DOI":"10.1111\/ejh.13527"},{"key":"6781_CR12","doi-asserted-by":"crossref","unstructured":"Othman TA, Zhang J, Mei M, Stein AS, Forman SJ, Marcucci G et al Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. Leuk Lymphoma. 2020-12-5;61(14).","DOI":"10.1080\/10428194.2020.1808213"},{"key":"6781_CR13","doi-asserted-by":"crossref","unstructured":"Tamellini E, Simio C, Bernardelli A, Ferrarini I, Vatteroni A, Moioli A et al Successful Rechallenge with Azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report. Annals Hematol 2024 103:10. 2024-08-03;103(10).","DOI":"10.1007\/s00277-024-05922-6"},{"issue":"6","key":"6781_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO, Ross DM, Powell JA, Pitson SM (2024) Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis 15(6):413","journal-title":"Cell Death Dis"},{"issue":"4","key":"6781_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/blood.2023021579","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Tiong IS, O\u2019Nions J, Dennis M, Mokretar K, Ivey A et al (2024) Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. Blood 143(4):336\u201341","journal-title":"Blood"},{"key":"6781_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-09745-2","volume":"10","author":"S Cocciardi","year":"2019","unstructured":"Cocciardi S, Dolnik A, Kapp-Schwoerer S, R\u00fccker FG, Lux S, Bl\u00e4tte TJ et al (2019) Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun 10:1 2019-05-02;10(1)","journal-title":"Nat Commun"},{"issue":"26","key":"6781_CR17","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AndrewH Wei","year":"2020","unstructured":"Wei Andrew H, D\u00f6hner H, Pocock C, Montesinos P, Afanasyev B, Dombret H et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383(26):2526\u201337","journal-title":"N Engl J Med"},{"key":"6781_CR18","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Myeloid Leukemia Version 2 (2026) \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline. https:\/\/www.nccn.org\/. Accessed 18 Nov 2025"},{"key":"6781_CR19","doi-asserted-by":"publisher","unstructured":"Schnegg-Kaufmann AS, Thoms JAI,\u00a0Bhuyan GS, Hampton HR, Vaughan L, Rutherford K, Kakadia PM, Lee HM, Johansson EMV, Failes\u00a0TW, Arndt GM, Koval J, Lindeman R, Warburton P, Rodriguez-Meira A, Mead AJ, Unnikrishnan A,\u00a0Davidson S, Polizzotto MN, Hertzberg M, Papaemmanuil E, Bohlander SK, Faridani OR, Jolly CJ,\u00a0Zanini F, Pimanda JE (2023) Contribution of mutant HSC clones to immature and mature cells in MDS\u00a0and CMML, and variations with AZA therapy. Blood 141(11):1316\u20131321.\u00a0https:\/\/doi.org\/10.1182\/blood.2022018602","DOI":"10.1182\/blood.2022018602"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06781-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:38Z","timestamp":1776405518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06781-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6781"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06781-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval is not required as per local HREC policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent for publication was obtained from patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}],"article-number":"120"}}